Raun, K., Hansen, B., Johansen, N., Thogersen, H., Madsen, K., Ankersen, M., & Andersen, P. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology , 139 (5), 552–561. https://doi.org/10.1530/eje.0.1390552 Venkova, K., Mann, W., Nelson, R., & Meerveld, B. G. (2009). Efficacy of Ipamorelin, a novel Ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of Pharmacology and Experimental Therapeutics/the Journal of Pharmacology and Experimental Therapeutics , 329 (3), 1110–1116. https://doi.org/10.1124/jpet.108.149211 Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. In Neuroendocrinology Letters, Neuroendocrinology Letters (Vol. 25, Issue 6, pp. 403–406). Neuroendocrinology Letters. https://www.nel.edu/userfiles/articlesnew/NEL250604A01.pdf Svensson, J., Lall, S., Dickson, S., Bengtsson, B., Romer, J., Ahnfelt-Ronne, I., Ohlsson, C., & Jansson, J. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology/Journal of Endocrinology , 165 (3), 569–577. https://doi.org/10.1677/joe.0.1650569

Information for Ipamorelin

Ipamorelin is a pentapeptide, meaning that its structure is comprised of five amino acids. It is a GH secretagogue, and is considered to be an agonist, meaning that it possesses the ability to bind certain receptors of a cell and provokes a cellular response.

Order Ipamorelin

Certificates of Analysis

Ipamorelin<br>7.09mg<br>Task #42400 <br>Batch #05072024<br>05/16/2024

Ipamorelin
7.09mg
Task #42400
Batch #05072024
05/16/2024

Ipamorelin Peptide Structure

Source: PubChem

Peptide Sequence: Aib-His-D-2Nal-D-Phe-Lys
Molecular Formula: C38H49N9O5
Molecular Weight: 711.868 g/mol
PubChem CID: 9831659
CAS Number: 170851-70-4

Order Ipamorelin

What Is Ipamorelin?

Upregulates production of growth hormone¹
May treat symptoms of postoperative ileus²

Stimulates the release of insulin³
Increases bone mineral content⁴

Research Studies

Raun, K., Hansen, B., Johansen, N., Thogersen, H., Madsen, K., Ankersen, M., & Andersen, P. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
Venkova, K., Mann, W., Nelson, R., & Meerveld, B. G. (2009). Efficacy of Ipamorelin, a novel Ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of Pharmacology and Experimental Therapeutics/the Journal of Pharmacology and Experimental Therapeutics, 329(3), 1110–1116. https://doi.org/10.1124/jpet.108.149211
Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. In Neuroendocrinology Letters, Neuroendocrinology Letters (Vol. 25, Issue 6, pp. 403–406). Neuroendocrinology Letters. https://www.nel.edu/userfiles/articlesnew/NEL250604A01.pdf
Svensson, J., Lall, S., Dickson, S., Bengtsson, B., Romer, J., Ahnfelt-Ronne, I., Ohlsson, C., & Jansson, J. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology/Journal of Endocrinology, 165(3), 569–577. https://doi.org/10.1677/joe.0.1650569

Product Usage

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Order Ipamorelin